These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1138 related items for PubMed ID: 19836166

  • 1. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):811-7. PubMed ID: 19836166
    [Abstract] [Full Text] [Related]

  • 2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 3. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, See A, Duchesne GM.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):1889-96. PubMed ID: 21550182
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J, Cambeiro M, Galán C, Teijeira M, Romero P, Zudaire J, Moreno M, Ciérvide R, Aristu JJ, Martínez-Monge R.
    Int J Radiat Oncol Biol Phys; 2010 Feb 01; 76(2):386-92. PubMed ID: 19427741
    [Abstract] [Full Text] [Related]

  • 5. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Katoh H, Noda SE, Ito K, Yamamoto T, Kashiwagi B, Nakano T.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):472-8. PubMed ID: 16168839
    [Abstract] [Full Text] [Related]

  • 6. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):e795-801. PubMed ID: 22330999
    [Abstract] [Full Text] [Related]

  • 7. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
    Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):814-9. PubMed ID: 18407435
    [Abstract] [Full Text] [Related]

  • 8. Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer.
    Soumarová R, Homola L, Stursa M, Perková H.
    Neoplasma; 2006 Nov 01; 53(5):410-7. PubMed ID: 17013535
    [Abstract] [Full Text] [Related]

  • 9. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results.
    Cury FL, Duclos M, Aprikian A, Patrocinio H, Kassouf W, Shenouda G, Faria S, David M, Souhami L.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):1417-23. PubMed ID: 21784585
    [Abstract] [Full Text] [Related]

  • 10. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA, Kestin LL, Martinez AA.
    Tech Urol; 2000 Jun 15; 6(2):135-45. PubMed ID: 10798815
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer.
    Gómez-Iturriaga Piña A, Crook J, Borg J, Lockwood G, Fleshner N.
    Urology; 2010 Jun 15; 75(6):1412-6. PubMed ID: 20035986
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
    Zebentout O, Apardian R, Beaulieu L, Harel F, Martin AG, Vigneault E.
    Cancer Radiother; 2010 Jun 15; 14(3):183-8. PubMed ID: 20418145
    [Abstract] [Full Text] [Related]

  • 16. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
    Mahmoudieh A, Tremblay C, Beaulieu L, Lachance B, Harel F, Lessard E, Pouliot J, Vigneault E.
    Radiother Oncol; 2005 Jun 15; 75(3):318-24. PubMed ID: 16086913
    [Abstract] [Full Text] [Related]

  • 17. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, Ozsoy O, Rouzaud M, Khan H, Miralbell R.
    Int J Radiat Oncol Biol Phys; 2009 Nov 01; 75(3):656-63. PubMed ID: 19250768
    [Abstract] [Full Text] [Related]

  • 18. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ, Nedelka MA, Arican ZL, Yamada Y, Cohen GN, Shippy AM, Park JJ, Zaider M.
    Brachytherapy; 2008 Nov 01; 7(1):1-6. PubMed ID: 18299108
    [Abstract] [Full Text] [Related]

  • 19. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T, Taussky D, Donath D, Le HP, Larouche RX, Béliveau-Nadeau D, Hervieux Y, Delouya G.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e377-83. PubMed ID: 21514068
    [Abstract] [Full Text] [Related]

  • 20. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S, Cesaretti J, Stone NN, Stock RG.
    BJU Int; 2006 Nov 15; 98(5):979-81. PubMed ID: 17034599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.